PARP1 and neoplasm: However, combining PARP inhibitors with immune checkpoint inhibitors (ICIs) may mitigate this challenge by targeting immunosuppressive myeloid cells and enhancing the overall anti-tumor response, potentially overcoming resistance mechanisms (Figure 1) (46).